As of June 18, 2025, Sarepta Therapeutics Inc (SRPT) reports a EV/EBITDA of -88.98.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Sarepta Therapeutics Inc's EV/EBITDA to Peers
To better understand Sarepta Therapeutics Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Sarepta Therapeutics Inc (SRPT) | -88.98 |
| TG Therapeutics Inc (TGTX) | 81.93 |
| Amicus Therapeutics Inc (FOLD) | 42.33 |
| Abbvie Inc (ABBV) | 18.34 |
| Amgen Inc (AMGN) | 15.43 |
| Regeneron Pharmaceuticals Inc (REGN) | 12.88 |
Compared to its competitors, Sarepta Therapeutics Inc's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.